Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

125 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies.
Rubin DT, Allegretti JR, Panés J, Shipitofsky N, Yarandi SS, Huang KG, Germinaro M, Wilson R, Zhang H, Johanns J, Feagan BG, Hisamatsu T, Lichtenstein GR, Bressler B, Peyrin-Biroulet L, Sands BE, Dignass A; QUASAR Study Group. Rubin DT, et al. Lancet. 2024 Dec 17:S0140-6736(24)01927-5. doi: 10.1016/S0140-6736(24)01927-5. Online ahead of print. Lancet. 2024. PMID: 39706209
Evaluation of the Effectiveness and Safety of Mesenchymal Stem Cell Treatment in Fistulising Crohn's Disease: An International Real-Life Retrospective Multicentre Cohort Study.
Bacsur P, Shaham D, Serclova Z, Resál T, Farkas B, Sarlós P, Miheller P, Maharshak N, Zemel M, Shitrit AB, Yellinek S, Bálint A, Fábián A, Bor R, Bősze Z, Ivány E, Szepes Z, Farkas K, Tóth I, Lázár G, Vlkova K, Tremerova A, Zuskova P, Ábrahám S, Molnár T. Bacsur P, et al. Among authors: miheller p. Aliment Pharmacol Ther. 2025 Jan;61(2):335-345. doi: 10.1111/apt.18359. Epub 2024 Oct 28. Aliment Pharmacol Ther. 2025. PMID: 39468719 Free PMC article.
Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis.
Sands BE, Feagan BG, Peyrin-Biroulet L, Danese S, Rubin DT, Laurent O, Luo A, Nguyen DD, Lu J, Yen M, Leszczyszyn J, Kempiński R, McGovern DPB, Ma C, Ritter TE, Targan S; ARTEMIS-UC Study Group. Sands BE, et al. N Engl J Med. 2024 Sep 26;391(12):1119-1129. doi: 10.1056/NEJMoa2314076. N Engl J Med. 2024. PMID: 39321363 Clinical Trial.
Transition is associated with lower disease activity, fewer relapses, better medication adherence, and lower lost-to-follow-up rate as opposed to self-transfer in pediatric-onset inflammatory bowel disease patients: results of a longitudinal, follow-up, controlled study.
Tóbi L, Prehoda B, Balogh AM, Nagypál P, Kovács K, Miheller P, Iliás Á, Dezsőfi-Gottl A, Cseh Á. Tóbi L, et al. Among authors: miheller p. Therap Adv Gastroenterol. 2024 May 31;17:17562848241252947. doi: 10.1177/17562848241252947. eCollection 2024. Therap Adv Gastroenterol. 2024. PMID: 39156978 Free PMC article.
End-to-end anastomosis provides similar quality-of-life, compared with other reconstructive techniques six months following total mesorectal excision: Systematic review and meta-analysis.
Kávási SB, Iov DE, Rancz A, Zolcsák Á, Veres DS, Lenti K, Miheller P, Hegyi P, Ábrahám S. Kávási SB, et al. Among authors: miheller p. Eur J Surg Oncol. 2024 Oct;50(10):108599. doi: 10.1016/j.ejso.2024.108599. Epub 2024 Aug 10. Eur J Surg Oncol. 2024. PMID: 39154431 Free article. Review.
Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease.
Peyrin-Biroulet L, Chapman JC, Colombel JF, Caprioli F, D'Haens G, Ferrante M, Schreiber S, Atreya R, Danese S, Lindsay JO, Bossuyt P, Siegmund B, Irving PM, Panaccione R, Cao Q, Neimark E, Wallace K, Anschutz T, Kligys K, Duan WR, Pivorunas V, Huang X, Berg S, Shu L, Dubinsky M; SEQUENCE Study Group. Peyrin-Biroulet L, et al. N Engl J Med. 2024 Jul 18;391(3):213-223. doi: 10.1056/NEJMoa2314585. N Engl J Med. 2024. PMID: 39018531 Clinical Trial.
[Semmelweis University Iron Board - Consensus statement of iron treatment].
Csulak E, Gellért B, Hritz I, Miheller P, Farkas P, Kovács G, Szabó A, Ács N, Becker D, Sydó N, Merkely B. Csulak E, et al. Among authors: miheller p. Orv Hetil. 2024 Jul 7;165(27):1027-1038. doi: 10.1556/650.2024.33078. Print 2024 Jul 7. Orv Hetil. 2024. PMID: 39002116 Hungarian.
Efficacy, drug sustainability, and safety of ustekinumab treatment in Crohn's disease patients over three years.
Barkai LJ, Gonczi L, Balogh F, Angyal D, Farkas K, Farkas B, Molnar T, Szamosi T, Schafer E, Golovics PA, Juhasz M, Patai A, Vincze A, Sarlos P, Farkas A, Dubravcsik Z, Toth TG, Szekely H, Miheller P, Lakatos PL, Ilias A. Barkai LJ, et al. Among authors: miheller p. Sci Rep. 2024 Jun 28;14(1):14909. doi: 10.1038/s41598-024-65987-1. Sci Rep. 2024. PMID: 38942890 Free PMC article.
A fekélyes vastagbélgyulladás gyógyszeres és sebészeti kezelése.
Miheller P, Kristóf T, Bor R, Farkas K, Golovics P, Harsányi L, Müller KE, Milassin Á, Palatka K, Schäfer E, Szamosi T, Sarlós P, Molnár T. Miheller P, et al. Orv Hetil. 2024 Mar 12;165(Supplement-1):37-64. doi: 10.1556/650.2024.33050. Print 2024 Mar 12. Orv Hetil. 2024. PMID: 38470491 Hungarian. No abstract available.
125 results